LISI, CHIARA
 Distribuzione geografica
Continente #
EU - Europa 63
AS - Asia 43
NA - Nord America 41
OC - Oceania 1
Totale 148
Nazione #
IT - Italia 47
US - Stati Uniti d'America 39
TH - Thailandia 21
SG - Singapore 13
GB - Regno Unito 9
CN - Cina 4
BG - Bulgaria 2
CA - Canada 2
FI - Finlandia 2
IN - India 2
RO - Romania 2
AU - Australia 1
ID - Indonesia 1
IL - Israele 1
NL - Olanda 1
TR - Turchia 1
Totale 148
Città #
Bangkok 21
Singapore 12
Rome 9
Milan 7
Santa Clara 6
Bologna 3
Craigavon 3
Ann Arbor 2
Ashburn 2
Chandler 2
Conroe 2
Florence 2
Fulham 2
Houston 2
Iasi 2
Los Angeles 2
Modena 2
New York 2
Palermo 2
Poolesville 2
Roncadelle 2
Sofia 2
Stevenage 2
Toronto 2
Wellingborough 2
Boardman 1
Cagliari 1
Cambridge 1
Helsinki 1
Istanbul 1
Jakarta 1
Lappeenranta 1
Piaggine 1
Princeton 1
San Diego 1
Seattle 1
Sydney 1
Tel Aviv 1
Wilmington 1
Woodbridge 1
Totale 112
Nome #
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab 65
Lymphadenopathies before and during the pandemic COVID-19: increasing incidence of metastases from solid tumors 40
null 27
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab 18
Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort 11
Benefits and Safety of Empiric Antibiotic Treatment Active Against KPC-Producing Klebsiella pneumoniae for Febrile Neutropenic Episodes in Colonized Children with Acute Leukemia—An 8-Year Retrospective Observational Study 2
Totale 163
Categoria #
all - tutte 715
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 715


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 1 12 0 0 0 1 0 5
2021/20226 0 0 0 0 1 2 0 0 2 0 1 0
2022/202324 2 0 0 0 1 1 13 6 0 0 1 0
2023/202451 6 6 7 3 2 6 2 4 0 2 3 10
2024/202563 21 4 7 12 19 0 0 0 0 0 0 0
Totale 163